Publications | Centro de Investigaciones Biológicas Margarita Salas - CIB Margarita Salas

Back

Kocak, M.; Ezazi Erdi, S.; Jorba, G.; Maestro, I.; Farrés, J.; Kirkin, V.; Martinez, A.; Pless, O. [2022]. Targeting autophagy in disease: established and new strategies. Autophagy 2022, 18, 473-495

Cuevas, E. P.; Rodríguez-Fernández, A.; Palomo, V.; Martínez, A.; Martín-Requero, Á. [2022]. TDP-43 pathology and prionic behavior in human cellular models of Alzheimer's disease patients. Biomedicines 2022, 10, 385

Maestro, I.; de la Ballina, L. R.; Porras, G.; Corrochano, S.; De Lago, E.; Simonsen, A.; Boya, P.; Martinez, A. [2022]. Discovery of mitophagy inhibitors with therapeutic potential in different familial Amyotrophic Lateral Sclerosis mutations. Int J Mol Sci 2022, 23, 12676.

Méndez-Líter, J. A.; Pozo-Rodríguez, A.; Madruga, E.; Rubert, M.; Santana, A. G.; de Eugenio, L. I.; Sánchez, C.; Martínez, A.; Prieto, A.; Martínez, M. J. [2022]. Glycosylation of epigallocatechin gallate by engineered glycoside hydrolases from Talaromyces amestolkiae: Potential antiproliferative and neuroprotective effect of these molecules. Antioxidants 2022, 11, 1325.

Alegría-Arcos, M.; Barbosa, T.; Sepúlveda, F.; Combariza, G.; González, J.; Gil, C.; Martínez, A.; Ramírez, D. [2022]. Network pharmacology reveals multi-target mechanism of action of drugs to be repurposed for COVID-19. Front Pharmacol 2022, 13, 952192.

Lastres-Becker, I.; de Lago, E.; Martínez, A.; Fernández-Ruiz, J. [2022]. New statement about NRF2 in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Biomolecules 2022, 12, 1200

Sebastián-Pérez, V.; Martinez de Iturrate, P.; Nácher-Vázquez, M.; Nóvoa, L.; Pérez, C.; Campillo, N. E.; Gil, C.; Rivas, L. [2022]. Naphthoquinone as a new chemical scaffold for leishmanicidal inhibitors of Leishmania GSK-3. Biomedicines 2022, 10, 11

Benitez-Fernandez, R.; Gil, C.; Guaza, C.; Mestre, L.; Martinez, A. [2022]. The dual PDE7-GSK3b inhibitor, VP3.15, as neuroprotective disease-modifying treatment in a model of primary progressive multiple sclerosis. Int J Mol Sci 2022, 23, 14378.

Alaohali, A.; Salzlechner, C.; Zaugg, L. K.; Suzano, F.; Martinez, A.; Gentleman, E.; Sharpe, P. T. [2022]. GSK3 inhibitor-induced dentinogenesis using a hydrogel. J Dent Res 2022, 101, 46-53.

Reggiori, F.; Boya, P.; da Costa, D.; Elazar, Z.; Eskelinen, E. L.; Farrés, J.; Guettler, S.; Kraftk, C.; Jungbluth, H.; Martinez, A.; Morel, E.; Pless, O.; Proikas-Cezanne, T.; Simonsen, A. [2022]. The mechanism of macroautophagy: the movie. Autophagy Rep 2022, 1, 414-417.

Cogram, P.; Fernández-Beltrán, L. C.; Casarejos, M. J.; Sánchez-Yepes, S.; Rodriguez-Martín, E.; García-Rubia, A.; Sánchez-Barrena, M. J.; Gil, C.; Martínez, A.; Mansilla, A. [2022]. Inhibition of NCS-1 binding to Ric8a rescues fragile X syndrome mice model phenotypes. Front Neurosci 2022, 16, 1007531.

Galindo, I.; Garaigorta, U.; Lasala, F.; Cuesta-Geijo, M. A.; Bueno, P.; Gil, C.; Delgado, R.; Gastaminza, P.; Alonso, C. [2021]. Antiviral drugs targeting endosomal membrane proteins inhibit distant animal and human pathogenic viruses. Antiviral Res. 2021, 186, 104990.

Sebastián-Pérez, V.; Sifaoui, I.; María Reyes-Batlle, M.; Domínguez-De Barros, A.; López-Arencibia, A.; Campillo, N. E.; Piñero, J. E.; Lorenzo-Morales, J.; Gil, C. [2021]. Discovery of amoebicidal compounds by combining computational and experimental approaches. Antimicrob. Agents Chemother. 2021, 65, e01749-20.

Lasala, F.; García-Rubia, A.; Requena, C.; Galindo, I.; Cuesta-Geijo, M. A.; García-Dorival, I.; Bueno, P.; Labiod, N.; Luczkowiak, J.; Martinez, A.; Campillo, N. E.; Alonso, C.; Delgado, R.; Gil, C. [2021]. Identification of potential inhibitors of protein-protein interaction useful to fight against Ebola and other highly pathogenic viruses. Antiviral Res. 2021, 186, 105011.

Berenguer, E.; Carneros, E.; Pérez-Pérez, Y.; Gil, C.; Martínez, A.; Testillano, P. S. [2021]. Small molecule inhibitors of mammalian GSK-3beta promote in vitro plant cell reprogramming and somatic embryogenesis in crop and forest species. J Exp Bot 2021, 72, 7808-7825.

Vaca, G.; Martínez-González, L.; Fernández, A.; Rojas-Prats, E.; Porras, G.; Cuevas, E. P.; Gil, C.; Martinez, A.; Martin-Requero, A. [2021]. Therapeutic potential of novel Cell Division Cycle Kinase 7 inhibitors on TDP-43-related pathogenesis such as Frontotemporal Lobar Degeneration (FTLD) and Amyotrophic Lateral Sclerosis (ALS). J Neurochem 2021, 156, 379-390.

Ginex, T.; Garaigorta, U.; Ramírez, D.; Castro, V.; Nozal, V.; Maestro, I.; García-Cárceles, J.; Campillo, N. E.; Martinez, A.; Gastaminza, P.; Gil, C. [2021]. Host-directed FDA-approved drugs with antiviral activity against SARS-CoV-2 identified by hierarchical in silico/in vitro screening methods. Pharmaceuticals 2021, 14, 332.

Nozal, V.; García-Rubia, A.; Cuevas, E. P.; Pérez, C.; Tosat-Bitrián, C.; Bartolomé, F.; Carro, E.; Ramírez, D.; Palomo, V.; Martínez, A. [2021]. From kinase inhibitors to multitarget ligands as powerful drug leads for Alzheimer's disease using protein-templated synthesis. Angew Chem Int Ed Engl 2021, 60 (35), 19344-19354.

García-Dorival, I.; Cuesta-Geijo, M. A.; Barrado-Gil, L.; Galindo, I.; Garaigorta, U.; Urquiza, J.; Del Puerto, A.; Campillo, N.; Martínez, A.; Gastaminza, P.; Gil, C.; Alonso, C. [2021]. Identification of Niemann-Pick C1 protein as a potential novel SARS-CoV-2 intracellular target. Antiviral Res 2021, 194, 105167.

Morales-Tenorio, M.; Ginex, T.; Cuesta-Geijo, M. A.; Campillo, N. E.; Muñoz-Fontela, C.; Alonso, C.; Delgado, R.; Gil, C. [2021]. Potential pharmacological strategies targeting the Niemann-Pick C1 receptor and Ebola virus glycoprotein interaction. Eur J Med Chem 2021, 223, 113654.